Protocol Ledger

NCT07220811 · Phase II · RECRUITING

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

Interventional Phase II clinical trial protocol NCT07220811 sponsored by GSK in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-22 Enrollment: 100 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07220811
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07220811
Protocol FieldVerified Registry Value
NCT IdentifierNCT07220811
Consolidated Lead SponsorGSK
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment100 participants (ESTIMATED)
Registered Start Date2025-10-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07220811
Hospital Research SiteLocationSite Profile
Children's Hospital ColoradoAurora, COOpen Hospital Dossier ->
National Jewish HealthDenver, COOpen Hospital Dossier ->
University of South FloridaTampa, FLOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI